However, Qi et al. (2003) reported that NEDD4-2 transcription was “enhanced” by an AR stimulation in prostate cancer, suggesting that an antiandrogen treatment “decreases” protein degradation via NEDD4-2. Here, NEDD4L is linked to prostate cancer.